Next Article in Journal
Mitochondrial Gene Expression and Beyond—Novel Aspects of Cellular Physiology
Next Article in Special Issue
Upregulation of Epithelial-To-Mesenchymal Transition Markers and P2X7 Receptors Is Associated to Increased Invasiveness Caused by P2X7 Receptor Stimulation in Human Glioblastoma Stem Cells
Previous Article in Journal
Multiple Sclerosis CD49d+CD154+ As Myelin-Specific Lymphocytes Induced During Remyelination
Previous Article in Special Issue
Relevance of Translation Initiation in Diffuse Glioma Biology and its Therapeutic Potential
Open AccessArticle

Identification of Astrocytoma Blood Serum Protein Profile

1
Laboratory of Molecular Neurooncology, Neuroscience Institute, Lithuanian University of Health Sciences, Eiveniu str. 4, LT50161 Kaunas, Lithuania
2
Laser Research Centre (VU LRC), Vilnius University, Sauletekio Ave 10, LT10223 Vilnius, Lithuania
*
Author to whom correspondence should be addressed.
Cells 2020, 9(1), 16; https://doi.org/10.3390/cells9010016
Received: 22 November 2019 / Revised: 11 December 2019 / Accepted: 16 December 2019 / Published: 19 December 2019
(This article belongs to the Special Issue Molecular and Cellular Mechanisms of Cancers: Glioblastoma)
High-grade astrocytomas are some of the most common and aggressive brain cancers, whose signs and symptoms are initially non-specific. Up to the present date, there are no diagnostic tools to observe the early onset of the disease. Here, we analyzed the combination of blood serum proteins, which may play key roles in the tumorigenesis and the progression of glial tumors. Fifty-nine astrocytoma patients and 43 control serums were analyzed using Custom Human Protein Antibody Arrays, including ten targets: ANGPT1, AREG, IGF1, IP10, MMP2, NCAM1, OPN, PAI1, TGFβ1, and TIMP1. The decision tree analysis indicates that serums ANGPT1, TIMP1, IP10, and TGFβ1 are promising combinations of targets for glioma diagnostic applications. The accuracy of the decision tree algorithm was 73.5% (75/102), which correctly classified 79.7% (47/59) astrocytomas and 65.1% (28/43) healthy controls. The analysis revealed that the relative value of osteopontin (OPN) protein level alone predicted the 12-month survival of glioblastoma (GBM) patients with the specificity of 84%, while the inclusion of the IP10 protein increased model predictability to 92.3%. In conclusion, the serum protein profiles of ANGPT1, TIMP1, IP10, and TGFβ1 were associated with the presence of astrocytoma independent of its malignancy grade, while OPN and IP10 were associated with GBM patient survival. View Full-Text
Keywords: astrocytoma; glioblastoma; serum proteins; Protein Antibody Array; decision tree; survival astrocytoma; glioblastoma; serum proteins; Protein Antibody Array; decision tree; survival
Show Figures

Graphical abstract

MDPI and ACS Style

Vaitkiene, P.; Urbanaviciute, R.; Grigas, P.; Steponaitis, G.; Tamasauskas, A.; Skiriutė, D. Identification of Astrocytoma Blood Serum Protein Profile. Cells 2020, 9, 16.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop